U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07152392) titled 'Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO' on June 21.
Brief Summary: Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter (Graves disease, GD). The clinical manifestations of TAO are complex and varied. In severe cases, it may seriously impair visual function, affect daily life, and even cause corneal ulceration, perforation, and blindness. Therefore, a reasonable and effective treatment plan should be chos...